Webinar

Recognizing IH: The Patient Diagnostic Journey

Launch Date

07/24/2023

Credit Amount

0.5

Credit Expires

12/31/2025

This activity is part of a series

Faculty

Michael J. Thorpy, MD

Professor of Neurology, Albert Einstein College of Medicine

Director, Sleep-Wake Disorders Center, Department of Neurology

Montefiore Medical Center, Bronx, NY

President, New York State Society of Sleep Medicine

Past President, Sleep Section of the Academy of Neurology

Paul P. Doghramji, MD, FAAFP

Senior Family Physician

Collegeville Family Practice

Medical Director, Health Services

Ursinus College

Collegeville, PA

Statement of Need

IH is characterized by excessive daytime sleepiness (EDS), severe sleep inertia, and prolonged, non-restorative nighttime sleep. Patients with IH report experiencing brain fog, poor memory, and sleep drunkenness, even though 50% of patients report sleeping 10 hours or more nightly. Quality of life (QoL) is worse in patients with IH compared to healthy patients, with IH contributing to worsened cognition, poor daily functioning, work absenteeism, and depression. However, clinician understanding of IH is poor, and recognition of signs and symptoms of IH may not be adequate. Findings indicate that patients can wait up to 5-10 years for a diagnosis to be given, indicating that clinicians lack familiarity with IH and the ability to correlate symptoms with the disease.

In this CMEO BriefCase, entitled Recognizing IH: The Patient Diagnostic Journey, expert faculty will walk through a case-driven discussion on the significant impact of symptoms on QoL and work/psychosocial functioning for patients with IH, and how this leads to delays in screening and diagnosis.

Learning Objective

Screen for IH based on clinical presentation or patient or family/caregiver description of function and changes in QoL.

Financial Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Target Audience

Sleep specialists, primary care physicians, pulmonologists, neurologists, psychiatrists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.

Activity UAN: JA0007185-0000-23-080-H01-P

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Thorpy reports the following financial relationships:

Advisory Board/Consultant: Alkermes; Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Ltd.; Takeda Pharmaceuticals U.S.A., Inc..; and XWPharma Ltd.

Dr. Doghramji reports the following financial relationships:

Advisory Board: Bayer; Eisai Inc.; and Idorsia Pharmaceuticals Ltd.

Speakers Bureau: AbbVie Inc. Eisai Inc.; Idorsia Pharmaceuticals Ltd; and Merck & Co., Inc.

Stock Shareholder (directly purchased): CVS Health Corporation and Pfizer Inc.

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
Evan Luberger (planning committee)
John Jones, PharmD (planning committee)
Susan H. Yarbrough, CHCP (planning committee)
Sandra Caballero, PharmD (planning committee)
Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.